文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性抗VEGF玻璃体内注射期间严重视力丧失:发生时机、预后及光学相干断层扫描表现

SEVERE VISUAL LOSS DURING ANTI-VEGF INTRAVITREAL INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: TIMING, PROGNOSIS, AND OPTICAL COHERENCE TOMOGRAPHY FINDINGS.
PubMed 文献 · Retina · 2023-01-01

该回顾性观察研究分析了2017年12月至2021年3月期间因新生血管性年龄相关性黄斑变性接受抗VEGF玻璃体内注射的1019只眼,发现15.1%的眼在两次连续注射间出现≥15个ETDRS字母的严重视力丧失,中位注射次数为6次,3个月时功能恢复显著而6个月时无进一步改善,作者认为应优先采用密切随访和主动治疗方案。

要点

  • 1019只眼中15.1%在两次连续抗VEGF注射间出现≥15个ETDRS字母视力丧失,中位发生在第6次注射。
  • 严重视力丧失常发生在诊断后9个月内及末次注射后2个月。
  • 3个月时功能恢复显著,6个月时无进一步改善。

核心结论

  • 作者认为,在新生血管性年龄相关性黄斑变性抗VEGF治疗期间,两次连续注射间发生≥15个ETDRS字母视力丧失并不少见,常发生在诊断后9个月内及末次注射后2个月。

研究设计与样本

  • 回顾性观察研究,纳入2017年12月至2021年3月因新生血管性年龄相关性黄斑变性接受抗VEGF玻璃体内注射的1019只眼,分析两次连续注射间突发严重视力下降(≥15个ETDRS字母丧失)的患者数据。
  • 每次注射前均行最佳矫正视力检查、光学相干断层扫描(OCT)及OCT血管成像(OCTA),并收集中央黄斑厚度(CMT)和注射药物。

主要发现

  • 1019只眼中15.1%发生严重视力丧失,中位注射次数为6次(范围1-38次)。
  • 严重视力丧失病例中,雷珠单抗注射占52.8%,阿柏西普注射占31.9%。
  • 3个月时功能恢复显著,6个月时无进一步改善。
  • 相对于CMT变化百分比,CMT无实质变化眼的视力预后优于CMT增加>20%或减少>5%的眼。

临床怎么用

  • 作者认为,至少在第一年应优先采用密切随访和主动治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) is the standard of care for neovascular age-related macular degeneration (nAMD). However, a small subgroup of patients still experience severe visual impairment, which may be related to the number of IVI administered. METHODS: This retrospective observational study analyzed data from patients with sudden severe visual decline (≥15 Early Treatment Diabetic Retinopathy Study [ETDRS] letters loss between two consecutive IVIs) during anti-VEGF treatment for nAMD. Best-corrected visual acuity examination, optical coherence tomography (OCT), and OCT angiography (OCTA) were performed before every IVI and central macular thickness (CMT) and drug injected were collected. RESULTS: 1,019 eyes received anti-VEGF IVI for nAMD from December 2017 to March 2021. Severe VA loss occurred in 15.1% after a median of 6 (range 1-38) IVI. Ranibizumab was injected in 52.8% and aflibercept in 31.9% of cases. Functional recovery after 3 months was significant, without further improvement at 6 months. Visual prognosis relative to the percentage of CMT change showed better visual outcome in eyes with no substantial change in CMT compared with an increase of >20% or a decrease of >5%. CONCLUSION: In this first real-life study exploring severe VA loss during anti-VEGF treatment in patients with nAMD, it was found that it was not unusual for a ≥15 ETDRS letters loss to occur between two consecutive IVIs, often within 9 months of diagnosis and 2 months after the last IVI. Close follow-up and a proactive regimen should be preferred, at least in the first year.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Grassi MO, Monteleone G, Pozharitskiy N, et al. SEVERE VISUAL LOSS DURING ANTI-VEGF INTRAVITREAL INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: TIMING, PROGNOSIS, AND OPTICAL COHERENCE TOMOGRAPHY FINDINGS. Retina. 2023. PMID: 36913628. doi:10.1097/IAE.0000000000003774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。